The pain and discomfort of recurrent urinary tract infections (UTIs) and cystitis could be relieved by a natural preventative ...

A group of experts who reviewed evidence on urinary tract infections (UTIs) failed to come up with many recommendations due ...

An elevated urinary sodium/potassium (Na/K) ratio is an independent risk factor for overactive bladder (OAB), investigators reported at the 2024 annual meeting of the International Continence Society ...

FDA approved Orlynvah for the Tx of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.

Investigators report findings from a study of 764 women younger than 40 years who participated in the Boston Area Community ...

BALTIMORE, Nov. 01, 2024 (GLOBE NEWSWIRE) -- November is Bladder Health Month, and this year the Urology Care Foundation is focusing on flushing out the myths and streaming in the facts about bladder ...

The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...

This makes it easier for an infection to travel to the bladder. UTIs are common. Men and women can get UTIs, but they are especially prevalent among women. Approximately 40 to 60 percent of women ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on ...

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.

ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades--Company ...